Similarly, another study demonstrated that the presence of co-mutations in the DDR pathway (including TP53) served as a predictor of response to atezolizumab in NSCLC, even in patients with negative or low PDL-1 expression [60]. Here, CD274 is linked to non-small cell lung carcinoma.